healthcare

FDA_logo

Repros Therapeutics Drops on FDA Vote

Repros Therapeutics Inc. (NASDAQ: RPRX) saw its shares take a loss on Wednesday after the company provided a key U.S. Food and Drug Administration (FDA) update. The company participated in ...
Read Full Story »
IPO

Tigenix Gears Up for IPO

TiGenix has filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company has not released any pricing data, but ...
Read Full Story »
Marijuana, Joint, Bud, Pot, Nug

Willie Nelson Reserve Marijuana Commands 50% Price Premium

Star power. There's nothing like it. It's the reason we see star athletes promoting footwear and other athletic gear and movie stars promoting just about anything. That star power is ...
Read Full Story »
ThinkstockPhotos-481735362

Teva Shares Slide on Management Change

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) shares sank on Tuesday after the company announced a change in its management. The company has appointed Dipankar Bhattacharjee as chief executive for its ...
Read Full Story »
Good heart health

Reata Pharma Files for Secondary Offering

Reata Pharmaceuticals Inc. (NASDAQ: RETA) has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for a secondary offering. The company did not disclose any pricing data, ...
Read Full Story »
FDA_logo

10 Major Pharma and FDA Catalysts Coming in December

Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a ...
Read Full Story »
blue eye

EyeGate Pharmaceuticals Continues to Win in Mid-Stage Trial

EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG) shares rose about 10% on Monday after the company announced promising data from its mid-stage trial of its leading product candidate. Specifically, the data came ...
Read Full Story »
Jon's friends

NeuroDerm Jumps on Critical FDA Update

NeuroDerm Ltd. (NASDAQ: NDRM) shares surged in Monday’s session following a critical update from the U.S. Food and Drug Administration (FDA). The company announced that after its End-of-Phase 2 meeting with ...
Read Full Story »
Marijuana background leaf

GW Pharmaceuticals Shows Smaller Than Expected Q4 Loss

GW Pharmaceuticals PLC (NASDAQ: GWPH) reported its fiscal fourth-quarter financial results before the markets opened on Monday. The company posted a net loss of $0.89 per share and $2.2 million ...
Read Full Story »
Unhealthy Person

Cempra Rises on Late-Stage Trial

Shares of Cempra Inc. (NASDAQ: CEMP) saw a handy gain early on Monday after Toyama Chemical announced that it had begun Phase 3 clinical trials with solithromycin in Japan for patients ...
Read Full Story »
Skunk in the Sun

Marijuana News Roundup: The ‘Trump-Effect’ Hits Cannabis-Related IPO

Last Thursday, a company named Innovative Industrial Properties Inc. (NYSE: IIPR) began trading on the New York Stock Exchange. The initial public offering (IPO) from the company was the first ...
Read Full Story »
cannabis plants

Marijuana Price Dips to $1,442 a Pound

For the week ended Friday, December 2, the spot price index for a pound of cannabis decreased by 1.3% from $1,461 in the prior week to $1,442. According to the ...
Read Full Story »
Doctor, Health (pulse) copy

Health Care Spending Reaches $3.2 Trillion, Nearly $10,000 per Person

Health care costs are on a rapid upturn, and with a vengeance in 2015. According to an article in Health Affairs, nationwide spending reached $3.2 trillion last year, up 5.8% ...
Read Full Story »
hospital entrance

Envision Healthcare Triples on Completed Merger

Shares of Envision Healthcare Holdings Inc. (NYSE: EVHC) more than tripled in Friday’s session after the company announced the completion of its merger with Amsurg. These health care companies are ...
Read Full Story »
Female patient on gurney

Recro Pharma Files for Secondary Offering Following Big Late-Stage Win

Recro Pharma Inc. (NASDAQ: REPH) saw its shares fall on Thursday after the company announced a secondary offering. No pricing details were given in the filing, but the offering is ...
Read Full Story »